Poractant Alfa - Curosurf and SARS-COV-19 ARDS (Covid-19)
Status:
Recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
The purpose of this Phase II -Proof of Concept study is to evaluate the efficacy and safety
of poractant alfa (Curosurf®), administered by endotracheal (ET) instillation in adult
hospitalized patients with SARS-COV-19 acute respiratory distress syndrome (ARDS)